Browsing by Author Hyman, Jessica

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2014BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impactBecker, Therese; Boyd, Suzanah; Carlino, Matteo; Fung, Carina; Haydu, Lauren; Howle, Julie; Kefford, Richard (Rick); Long, Georgina; Mijatov, Branka; Pupo, Gulietta; Rizos, Helen; Saw, Robyn; Scolyer, Richard; Thompson, John; Hyman, Jessica; Menzies, Alexander; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Infectious Diseases; Central Clinical School: Surgery; Western Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: SurgeryBRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact, Clinical Cancer Research, vol.20, 7, 2014,pp 1965-1977
2015Coherence analysis discriminates between retroviral integration patterns in CD34(+) cells transduced under differing clinical trial conditionsAlexander, Ian; Ginn, Samantha; Liddle, Christopher; et al, Various; Garg, Gagan; Hallwirth, Claus V.; Hetherington, Nicola; Hyman, Jessica; Kramer, Belinda; Malani, Nirav V; Peters, Timothy J; Ruan, Xiaoan; Shahab, Atif; Veeravalli, Lavanya; Childrens Medical Research Institute (CMRI); Childrens Medical Research Institute (CMRI); Western Clinical School: Medicine (Westmead)Coherence analysis discriminates between retroviral integration patterns in CD34(+) cells transduced under differing clinical trial conditions, Molecular Therapy - Methods & Clinical Development, vol.2, N/A, 2015,pp 1-10
2014Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatmentHaydu, Lauren; Hersey, Peter; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Scolyer, Richard; Thompson, John; Wilmott, James; Hyman, Jessica; Lum, Trina; Central Clinical School: Surgery; Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: SurgeryDynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment, The Journal of Immunology, vol.192, 5, 2014,pp 2505-2513
2014Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanomaCarlino, Matteo; Fung, Carina; Howle, Julie; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Pupo, Gulietta; Rizos, Helen; Saw, Robyn; Scolyer, Richard; Shahheydari, Hamideh; Tembe, Varsha; Thompson, John; Hayward, Nicholas K; Hyman, Jessica; Johansson, Peter; Western Clinical School: Medicine (Westmead); Infectious Diseases; Western Clinical School: Surgery; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Central Clinical School: Surgery; Central Clinical School: Pathology; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Central Clinical School: SurgeryIncreased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma, Nature Communications, vol.5, N/A, 2014,pp 1-9
2014Intrapatient Homogeneity of BRAFV600E Expression in MelanomaHyman, Jessica; Kefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; O'Toole, Sandra; Scolyer, Richard; Thompson, John; Wilmott, James; Lum, Trina; Melanoma Foundation; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: SurgeryIntrapatient Homogeneity of BRAFV600E Expression in Melanoma, The American Journal of Surgical Pathology, vol.38, 3, 2014,pp 377-382
2010Lymphomagenesis in SCID-X1 Mice Following Lentivirus-mediated Phenotype Correction Independent of Insertional Mutagenesis and gammac Overexpression.Alexander, Ian; Alexander, Stephen; Hu, Min; Cavazzana-Calvo, Marina; Dane, Alison; Finnie, John W.; Ginn, Samantha L; Hyman, Jessica; Liao, Sophia; Thrasher, Adrian; Zheng, Maolin; Children's Hospital Westmead: Paediatrics & Child Health; Children's Hospital Westmead: Paediatrics & Child Health; Children's Hospital Westmead: Childrens Medical Research InsLymphomagenesis in SCID-X1 Mice Following Lentivirus-mediated Phenotype Correction Independent of Insertional Mutagenesis and gammac Overexpression., Molecular Therapy, vol.18, 5,pp 965-976
2015PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trialsHersey, Peter; Kakavand, Hojabr; Kefford, Richard (Rick); Long, Georgina; Madore, Jason; Menzies, Alexander Maxwel; Scolyer, Richard; Thompson, John; Vilain, Ricardo; Wilmott, James; Hyman, Jessica; Yearley, Jennifer H; Northern Clinical School: Surgery; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Central Clinical School: Medicine; Central Clinical School: Pathology; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: SurgeryPD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials, Pigment Cell & Melanoma Research, vol.28, 3, 2015,pp 245-253